Time-resolved dose reconstruction by motion encoding of volumetric modulated arc therapy fields delivered with and without dynamic multi-leaf collimator tracking.
| Field | Value | Language |
| dc.contributor.author | Rakvilde, T | |
| dc.contributor.author | Keall, P | |
| dc.contributor.author | Grau, C | |
| dc.contributor.author | Høyer, M | |
| dc.contributor.author | Poulsen, PR | |
| dc.date.accessioned | 2018-07-06 | |
| dc.date.available | 2018-07-06 | |
| dc.date.issued | 2013-10-01 | |
| dc.identifier.citation | Acta Oncol. 2013 Oct;52(7):1497-503 | en |
| dc.identifier.uri | http://hdl.handle.net/2123/18536 | |
| dc.description.abstract | BACKGROUND: Organ motion during treatment delivery in radiotherapy (RT) may lead to deterioration of the planned dose, but can be mitigated by dynamic multi-leaf collimator (DMLC) tracking. The purpose of this study was to implement and experimentally validate a method for time-resolved motion including dose reconstruction for volumetric modulated arc therapy (VMAT) treatments delivered with and without DMLC tracking. MATERIAL AND METHODS: Tracking experiments were carried out on a linear accelerator (Trilogy, Varian) with a prototype DMLC tracking system. A motion stage carrying a biplanar dosimeter phantom (Delta4PT, Scandidos) reproduced eight representative clinical tumor trajectories (four lung, four prostate). For each trajectory, two single-arc 6 MV VMAT treatments with low and high modulation were delivered to the moving phantom with and without DMLC tracking. An existing in-house developed program that adds target motion to treatment plans was extended with the ability to split an arc plan into any number of sub-arcs, allowing the calculated dose for different parts of the treatment to be examined individually. For each VMAT sub-arc, reconstructed and measured doses were compared using dose differences and 3%/3 mm γ-tests. RESULTS: For VMAT sub-arcs the reconstructed dose distributions had a mean root-mean-square (rms) dose difference of 2.1% and mean γ failure rate of 2.0% when compared with the measured doses. For final accumulated doses the mean rms dose difference was 1.6% and the γ failure rate was 0.7%. CONCLUSION: The time-resolved motion including dose reconstruction was experimentally validated for complex tracking and non-tracking treatments with patient-measured tumor motion trajectories. The reconstructed dose will be of high value for evaluation of treatment plan robustness facing organ motion and adaptive RT. | en |
| dc.publisher | Taylor & Francis | en |
| dc.relation | NHMRC 633000 | en |
| dc.rights | Other | |
| dc.subject | MLC tracking | en |
| dc.title | Time-resolved dose reconstruction by motion encoding of volumetric modulated arc therapy fields delivered with and without dynamic multi-leaf collimator tracking. | en |
| dc.type | Article | en |
| dc.subject.asrc | 029903 | en |
| dc.identifier.doi | 10.3109/0284186X.2013.818248 | |
| dc.type.pubtype | Preprint | en |
| usyd.faculty | Faculty of Medicine and Health, Sydney Medical School | en |
Associated file/s
Associated collections